Several clinical trials have clearly demonstrated that high EGFR expression strongly correlates with poor prognosis and lower response rate after standard radiotherapy or chemoradiation in patients affected by LA SCCHN [31,32]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.